A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

She believed that had she had a CA125 blood test earlier - CA125 is a protein in the blood and can be raised in women with ...

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Polymer-coated nanoparticles loaded with therapeutic drugs show significant promise for cancer treatment, including ovarian ...

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, ...

In 2022, more than 13,000 people died from ovarian cancer, according to the CDC. A common blood test for ovarian cancer is ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

After you’ve gone through ovarian cancer treatment, your doctor will work with you to make sure you stay well. But sometimes the cancer returns. Doctors call this “recurrence.” To check for ...